Your browser is no longer supported. Please, upgrade your browser.
ACHN Achillion Pharmaceuticals, Inc. daily Stock Chart
Achillion Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.51 Insider Own0.15% Shs Outstand142.22M Perf Week67.77%
Market Cap866.12M Forward P/E- EPS next Y-0.78 Insider Trans-38.49% Shs Float139.44M Perf Month61.11%
Income-70.90M PEG- EPS next Q-0.16 Inst Own82.30% Short Float5.76% Perf Quarter119.86%
Sales- P/S- EPS this Y18.30% Inst Trans0.22% Short Ratio2.82 Perf Half Y99.02%
Book/sh1.67 P/B3.65 EPS next Y-26.20% ROA-26.30% Target Price8.65 Perf Year96.45%
Cash/sh1.64 P/C3.71 EPS next 5Y17.58% ROE-27.60% 52W Range1.29 - 6.44 Perf YTD283.02%
Dividend- P/FCF- EPS past 5Y4.10% ROI- 52W High-5.43% Beta1.52
Dividend %- Quick Ratio14.60 Sales past 5Y- Gross Margin- 52W Low372.09% ATR0.35
Employees56 Current Ratio14.60 Sales Q/Q- Oper. Margin- RSI (14)78.85 Volatility4.31% 5.58%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.70% Profit Margin- Rel Volume2.24 Prev Close6.20
ShortableYes LT Debt/Eq0.00 EarningsNov 06 BMO Payout- Avg Volume2.85M Price6.09
Recom2.50 SMA2054.63% SMA5045.28% SMA20092.12% Volume6,386,438 Change-1.77%
Oct-18-19Downgrade SVB Leerink Outperform → Mkt Perform $5 → $6.30
May-21-18Upgrade Barclays Underweight → Equal Weight $5
Feb-08-18Initiated B. Riley FBR, Inc. Neutral $3.50
Sep-12-17Reiterated Ladenburg Thalmann Buy $9 → $6.50
Aug-10-17Downgrade Robert W. Baird Outperform → Neutral $5
Aug-09-17Reiterated Chardan Capital Markets Neutral $5 → $4
May-18-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-02-17Initiated Ladenburg Thalmann Buy $10
Nov-04-16Upgrade Chardan Capital Markets Sell → Neutral $5
Sep-23-16Reiterated Chardan Capital Markets Sell $4 → $5
Sep-23-16Initiated Wedbush Outperform $13
Sep-15-16Initiated FBR & Co. Outperform $16
Jul-14-16Initiated Chardan Capital Markets Sell $4
Jul-07-16Upgrade JMP Securities Mkt Perform → Mkt Outperform
Feb-26-16Upgrade Robert W. Baird Neutral → Outperform $10
Feb-25-16Reiterated Maxim Group Buy $11 → $8
Sep-09-15Initiated Jefferies Hold
Aug-13-15Reiterated Maxim Group Buy $19 → $11
May-20-15Reiterated Leerink Partners Outperform $25 → $16
May-20-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-19-19 10:30AM  INVESTOR ALERT: Monteverde & Associates PC Is Investingating The Merger ACCESSWIRE
Oct-18-19 04:50PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc. PR Newswire
12:05PM  Will Soliris Aid Growth for Alexion (ALXN) in Q3 Earnings? Zacks
12:00PM  SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues To Investigate Whether The Sale Of These Companies Is Fair To Shareholders - RARX, DOVA, ACHN ACCESSWIRE
07:04AM  Alexion to Buy Achillion for $930M, Strengthen PNH Franchise Zacks
Oct-17-19 12:22PM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on Behalf of Achillion Shareholders and Encourages Achillion Investors to Contact the Firm PR Newswire
07:39AM  The Daily Biotech Pulse: FDA Panel Backs Shionogi's Antibiotic, Hepion Surges On Data Publication, Innate Pharma IPO Benzinga
Oct-16-19 09:35PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Achillion Pharmaceuticals, Inc. (NASDAQ GS: ACHN) ACCESSWIRE +71.78%
03:05PM  Montco biotech firm sold for $930M, shares soar American City Business Journals
12:00PM  ACHILLION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout ACCESSWIRE
11:43AM  Alexion makes $930M acquisition in bid to bolster blockbuster drug American City Business Journals
11:38AM  ACHILLION MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Achillion Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm ACHN GlobeNewswire
11:15AM  Achillion Pharmaceuticals Stock Soars on Deal to Be Acquired by Alexion
10:44AM  Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Achillion Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Alexion Pharmaceuticals, Inc. PR Newswire
08:50AM  Achillion (ACHN) Alert: Johnson Fistel Investigates Proposed Sale of Achillion Pharmaceuticals; Are Shareholders Getting a Fair Deal? PR Newswire
07:25AM  Alexion To Acquire Achillion Pharma For $930M Benzinga
07:15AM  Achillion Pharmaceuticals' stock rockets after Alexion Pharmaceuticals $930 million buyout deal MarketWatch
06:41AM  Drugmaker Alexion to buy biotech Achillion in $930 mln deal Reuters
06:30AM  Alexion to Acquire Achillion Business Wire
06:00AM  Alexion Pharmaceuticals to Acquire Achillion in $930 Million Deal
Sep-26-19 11:32AM  Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN Zacks
08:32AM  Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-25-19 07:21AM  [video]Achillion Pharma Stock Soars as New Drug Gets FDA Breakthrough Status
07:00AM  Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria GlobeNewswire
Sep-19-19 06:19AM  How Much Cash Is Left In The Bank For Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)? Simply Wall St.
Sep-07-19 09:30AM  Why Is Achillion (ACHN) Down 11.2% Since Last Earnings Report? Zacks
Aug-29-19 05:00PM  Achillion to Present at the Baird 2019 Global Healthcare Conference GlobeNewswire
Aug-09-19 08:24AM  Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil Zacks
Aug-08-19 07:30AM  Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire +8.56%
Jul-26-19 05:29PM  Why Achillion Pharmaceuticals Stock Flew Higher Again Today Motley Fool +18.02%
Jul-23-19 12:30PM  Why Achillion Pharmaceuticals Stock Is Soaring Again Today Motley Fool +28.88%
Jul-22-19 05:50PM  Why Luckin Coffee, Beyond Meat, and Achillion Pharmaceuticals Jumped Today Motley Fool +16.39%
03:41PM  Why Achillion Pharmaceuticals Stock Jumped Today Motley Fool
07:00AM  Achillions ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers GlobeNewswire
Jul-17-19 06:00AM  Achillion Pharmaceuticals ACHN- 2019 Top Picks' Mid-Year Update MoneyShow
Jul-10-19 09:23AM  Does Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Have A High Beta? Simply Wall St.
Jul-04-19 08:35AM  Alexion's Ultomiris Receives EU Approval for PNH in Adults Zacks
Jun-28-19 08:45AM  Alexion Receives FDA Approval for Label Expansion of Soliris Zacks
Jun-26-19 06:29PM  Heres What Hedge Funds Think About Achillion Pharmaceuticals, Inc. (ACHN) Insider Monkey
Jun-21-19 11:05AM  Alexion's sBLA for Ultomiris Gets Priority Review From FDA Zacks
Jun-13-19 07:00AM  Achillion to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-10-19 07:00AM  Achillion Announces Upcoming Scientific Presentation at the 24th Congress of the European Hematology Association GlobeNewswire
Jun-08-19 09:30AM  Why Is Achillion (ACHN) Down 1.4% Since Last Earnings Report? Zacks
May-17-19 08:03AM  The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering Benzinga
07:00AM  Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting GlobeNewswire
May-14-19 06:00AM  Achillion Granted Twentieth Patent for Factor D Portfolio GlobeNewswire +7.66%
May-13-19 09:13AM  Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1 Zacks -5.84%
May-11-19 08:40AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs Benzinga
May-09-19 04:00PM  What You Need to Know About Achillion Pharmaceuticals' Q1 Update Motley Fool
10:19AM  Achillion: 1Q Earnings Snapshot Associated Press
06:00AM  Achillion Reports First Quarter 2019 Financial Results GlobeNewswire
May-02-19 06:00AM  Biotech Bets and a Goodbye from a Favorite Expert MoneyShow
Apr-06-19 09:30AM  Why Is Achillion (ACHN) Up 25.6% Since Last Earnings Report? Zacks
Apr-04-19 10:23AM  Achillion Meets Enrollment Target in Kidney Disease Studies Zacks
Apr-03-19 12:50PM  Why Achillion Pharmaceuticals Stock Is Jumping Today Motley Fool
06:00AM  Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy GlobeNewswire
Mar-28-19 04:41PM  Achillion Completes Enrollment in Rare Blood Disorder Study Zacks
Mar-27-19 06:00AM  Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial GlobeNewswire
Mar-13-19 01:09PM  Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Are Analysts Right About The Drop In Earnings? Simply Wall St.
Mar-08-19 10:04AM  Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4 Zacks
06:00AM  Achillion to Present at the Barclays Global Healthcare Conference GlobeNewswire
Mar-07-19 06:00AM  Achillion Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-21-19 12:57PM  Why a Connecticut pharma firm moved its C-suite to Blue Bell American City Business Journals
06:00AM  Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market GlobeNewswire
Feb-19-19 06:00AM  Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference GlobeNewswire
Feb-12-19 07:50AM  Research Report Identifies The Goodyear Tire & Rubber, Prudential Financial, PennyMac Mortgage Investment Trust, Achillion Pharmaceuticals, American Software, and Lantheus with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-11-19 06:00AM  Achillion Appoints Brian Di Donato as Chief Financial Officer GlobeNewswire
Feb-04-19 12:45PM  Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up Zacks
Jan-31-19 06:00AM  Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers GlobeNewswire
Jan-29-19 11:10AM  Alexion's Ultomiris Meets Primary Endpoint in aHUS Study Zacks
Jan-10-19 10:49AM  Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December Motley Fool
05:00AM  Top Picks 2019- Achillian Pharmaceuticals ACHN MoneyShow
Jan-03-19 07:36AM  The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen Benzinga
06:00AM  Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors GlobeNewswire
Dec-31-18 10:50AM  4 Healthcare Stocks That Are Raising Eyebrows ACCESSWIRE +7.43%
Dec-20-18 04:30PM  Why Achillion Pharmaceuticals Plunged for a 4th Consecutive Day Motley Fool -19.51%
Dec-19-18 03:45PM  Why Achillion Pharmaceuticals Sank Again Today Motley Fool -15.90%
Dec-18-18 05:32PM  Achillion Reports Positive Interim Data on Factor D Inhibitors Zacks -18.75%
04:33PM  Why Rent-A-Center, Achillion Pharmaceuticals, and BP Prudhoe Bay Slumped Today Motley Fool
03:02PM  Why Achillion Pharmaceuticals Is Cratering Again Today Motley Fool
08:00AM  The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan Benzinga
06:50AM  Today's Research Reports on Trending Tickers: Achillion Pharmaceuticals and Synergy Pharmaceuticals ACCESSWIRE
Dec-17-18 04:33PM  Why Achillion Pharmaceuticals Crashed Today Motley Fool -22.83%
04:02PM  Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Trials and Provides Clinical Development Strategy Update GlobeNewswire
Dec-16-18 02:18PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Dec-12-18 01:15AM  Should You Buy Achillion Pharmaceuticals, Inc. (ACHN)? Insider Monkey
Dec-10-18 06:00AM  Achillion Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018 GlobeNewswire
Dec-08-18 06:19PM  RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy? Insider Monkey
Dec-03-18 09:00AM  Implied Volatility Surging for Achillion (ACHN) Stock Options Zacks +7.96%
Nov-07-18 06:30AM  Achillion: 3Q Earnings Snapshot Associated Press
06:00AM  Achillion Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-18-18 01:14PM  Does Achillion Pharmaceuticals Inc (NASDAQ:ACHN) Have A Volatile Share Price? Simply Wall St.
Oct-17-18 07:40AM  Investor Expectations to Drive Momentum within SunOpta, Acorda Therapeutics, Sapiens International Corporation N.V, The Descartes Systems Group, Achillion Pharmaceuticals, and CSS Industries Discovering Underlying Factors of Influence GlobeNewswire
Sep-25-18 06:00AM  Achillion to Present at the Leerink Partners Roundtable Series GlobeNewswire
Sep-14-18 09:09AM  The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion Zacks
Sep-13-18 09:14AM  IPOs and Foreign Investment Propel Biotech: 4 Top Picks Zacks
Sep-10-18 06:00AM  Achillion Appoints Paul Firuta Chief Operating Officer GlobeNewswire
Sep-07-18 09:30AM  Why Is Achillion (ACHN) Up 24.7% Since Last Earnings Report? Zacks
Aug-31-18 04:14AM  Achillion Pharmaceuticals (ACHN) Shares March Higher, Can It Continue? Zacks +8.49%
Aug-30-18 06:00AM  Achillion to Present at the Baird 2018 Global Healthcare Conference GlobeNewswire
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in Blue Bell, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Truitt JosephChief Executive OfficerOct 16Option Exercise3.14133,484419,785136,984Oct 18 05:13 PM
Truitt JosephChief Executive OfficerOct 16Sale6.37133,484850,9473,500Oct 18 05:13 PM
Scheer DavidDirectorDec 14Option Exercise1.0520,00021,00020,000Dec 18 04:24 PM
VAN NOSTRAND ROBERT LDirectorDec 14Option Exercise1.0520,00021,00020,000Dec 18 04:22 PM